X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SP-103 (lidocaine topical system) 5.4% triple strength formulation for ZTlido®, is being investigated in subjects with moderate to severe acute lower back pain (LBP).
Lead Product(s): Lidocaine
Therapeutic Area: Neurology Product Name: SP-103
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
Ovydso (STI-1558) is a prodrug, and its active form AC1115 binds to Cys-145 of catalytic domain of Mpro, which is 100% conserved in all SARS-CoV-2 variants and achieves a broad-spectrum anti-SARS-CoV-2 activity, including Delta and Omicron strains.
Lead Product(s): Olgotrelvir
Therapeutic Area: Infections and Infectious Diseases Product Name: Ovydso
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
RTX (resiniferatoxin) is a small molecule which is act as TRPV1 agonist, which is investigated for the treatment of knee pain in moderate to severe osteoarthritis of the knee (OAK) patients.
Lead Product(s): Resiniferatoxin
Therapeutic Area: Musculoskeletal Product Name: RTX
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
STI-5656 (abivertinib maleate) is a pyrrolopyrimidine-based, mutant EGFR and BTK dual inhibitor with potential across multiple indications like Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL).
Lead Product(s): Abivertinib
Therapeutic Area: Oncology Product Name: STI-5656
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2023
Details:
Ovydso (STI-1558) is a prodrug, and its active form AC1115 binds to Cys-145 of catalytic domain of Mpro, which is 100% conserved in all SARS-CoV-2 variants and achieves a broad-spectrum anti-SARS-CoV-2 activity, including Delta and Omicron strains.
Lead Product(s): Olgotrelvir
Therapeutic Area: Infections and Infectious Diseases Product Name: Ovydso
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
Ovydso (STI-1558) is a prodrug, and its active form AC1115 binds to Cys-145 of catalytic domain of Mpro , which is 100% conserved in all SARS-CoV-2 variants and achieves a broad-spectrum anti-SARS-CoV-2 activity, including Delta and Omicron strains.
Lead Product(s): STI-1558
Therapeutic Area: Infections and Infectious Diseases Product Name: Ovydso
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
STI-1557 is a next generation mRNA vaccine against SARS-CoV-2 Omicron variants. This mRNA vaccine incorporates a mutation in the furin cleavage site that prevents the S1 subunit cleavage from the spike protein from anchoring on the muscle cell membrane.
Lead Product(s): STI-1557
Therapeutic Area: Infections and Infectious Diseases Product Name: STI-1557
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
IMC-001 is a PD-L1 antibody, a fully human immune checkpoint inhibitor, that activates the anticancer functions of T cells by strongly inhibiting the binding between PD-1 expressed on T cells and PD-L1 expressed on the surface of cancer cells.
Lead Product(s): IMC-001
Therapeutic Area: Oncology Product Name: IMC-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
Overall, STI-1558 was well-tolerated at these doses with most subjects reporting no adverse events (AEs). There was no dose limiting toxicity during the study. There were no severe or serious AEs, no premature discontinuation of STI-1558 due to an AE, and no deaths.
Lead Product(s): STI-1558
Therapeutic Area: Infections and Infectious Diseases Product Name: STI-1558
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
The NTM device was applied to the dorsal forearm and etanercept infused for 1.25 hours. The device was alternately applied between the left and right forearms every other week.
Lead Product(s): Etanercept
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: 4P Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
